The excitement around Moderna’s cancer vaccine is cooling. Here’s why.

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.

Source:MarketWatch
Disclaimer:Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.